# DNA Testing Simplification & Access Strategy

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Innovation Officer
**Purpose**: Simplify AATD genetic testing processâ€”making testing faster, cheaper, more accessible through partnerships, technology innovation, and policy advocacy

---

## ðŸ“‹ Table of Contents

1. [Overview](#overview)
2. [Current Testing Landscape](#current-testing-landscape)
3. [Barriers to Testing](#barriers-to-testing)
4. [Simplification Strategies](#simplification-strategies)
5. [Consumer Genetics Partnership](#consumer-genetics-partnership)
6. [At-Home Testing Program](#at-home-testing-program)
7. [Insurance & Reimbursement](#insurance--reimbursement)
8. [Technology Innovation](#technology-innovation)
9. [Implementation Roadmap](#implementation-roadmap)
10. [Success Metrics](#success-metrics)

---

## Overview

### The Testing Problem

**AATD diagnosis requires TWO tests**:

1. **AAT Level Test** (serum)â€”measures circulating Alpha-1 Antitrypsin protein (identifies deficiency)
2. **Genetic Test** (DNA)â€”confirms genotype (ZZ, MZ, MS, rare variantsâ€”determines severity, inheritance)

**Current Reality**:

- Only 25% of suspected AATD patients complete BOTH tests (75% stop after AAT levelâ€”don't get genetic confirmation)
- Genetic test costs $200-$1,000 (insurance coverage variable)
- Requires separate lab visit (another needle stick, more waiting)
- Results take 2-4 weeks (patients lose motivation)
- Limited access (rural patients, uninsured, international)

**Result**: 300,000+ Americans undiagnosed (have AATD but never confirmed genetically)

---

### Vision: Make AATD Testing as Easy as 23andMe

**Goals**:

- âœ… **One Test**: AAT level + genetics in single sample (no separate genetic test needed)
- âœ… **At-Home**: Mail-in kit (spit or finger prickâ€”no clinic visit)
- âœ… **Affordable**: $50-$100 (insurance reimbursed, or Foundation subsidizes)
- âœ… **Fast**: Results in 1-2 weeks (vs. 4-6 weeks current process)
- âœ… **Accessible**: Available nationwide (rural, uninsured, international)
- âœ… **Actionable**: Results include next steps (referral to specialist, genetic counseling, Foundation resources)

**Impact**: 10x increase in genetic testing completion (250Kâ†’2.5M tests over 10 years)

---

## Current Testing Landscape

### Standard AATD Genetic Testing Process

**Step 1: Abnormal AAT Level**:

- Patient has low AAT level (<90 mg/dLâ€”suggests deficiency)
- Doctor orders genetic test (SERPINA1 gene sequencing)

**Step 2: Genetic Test Order**:

- Doctor completes lab requisition (Quest, LabCorp, specialty labs like ARUP, Mayo)
- Specifies test type:
  - **Targeted genotyping** ($200-$400â€”tests only common variants: S, Z)
  - **Full gene sequencing** ($500-$1,000â€”identifies rare variants)

**Step 3: Patient Sample Collection**:

- Patient returns to lab (another appointment)
- Blood draw (venipunctureâ€”5-10 mL)
- Sample shipped to lab (sometimes sent to specialty labâ€”adds time)

**Step 4: Lab Processing**:

- **PCR-based genotyping** (2-3 daysâ€”for common variants)
- **Sanger sequencing** (1-2 weeksâ€”for full gene)
- **Next-gen sequencing** (NGSâ€”1-2 weeks, more comprehensive)

**Step 5: Results & Follow-Up**:

- Results sent to doctor (2-4 weeks total)
- Doctor calls patient (discuss results, next steps)
- If confirmed AATD (ZZ, SZ, rare null variants) â†’ refer to pulmonologist, genetic counseling

**Total Time**: 4-6 weeks (from AAT level to genetic confirmation)

---

### Who Offers AATD Genetic Testing (Current Market)

**Clinical Labs**:

- Quest Diagnostics, LabCorp (national labsâ€”targeted genotyping)
- ARUP Laboratories (University of Utahâ€”full sequencing, rare variants)
- Mayo Clinic Laboratories (comprehensive testing)
- GeneDx, Invitae (specialty genetic testing companies)

**Research Programs**:

- Alpha-1 Foundation (free testing programâ€”research-focused, requires consent to use data)
- University research studies (free testing, but limited availability)

**Direct-to-Consumer** (Limited):

- 23andMe includes some AATD variants (S, Zâ€”but not comprehensive, many false negatives)
- Not widely used for clinical diagnosis (doctors don't trust results)

---

## Barriers to Testing

### 1. Cost Barrier

**Problem**:

- Genetic test costs $200-$1,000 (varies by lab, test type)
- Insurance coverage variable (some plans cover 100%, others deny or high copay)
- Uninsured patients pay full price (can't affordâ€”skip test)

**Impact**: 30% of patients cite cost as reason for not completing genetic test

---

### 2. Access Barrier

**Problem**:

- Requires lab visit (blood drawâ€”not all clinics offer, rural patients travel 50+ miles)
- Not available internationally (many countries lack AATD testing infrastructure)
- Doctor must order (some won'tâ€”low awareness, think it's unnecessary)

**Impact**: 20% of patients can't access testing (rural, international, doctor refusal)

---

### 3. Complexity Barrier

**Problem**:

- Two-step process (AAT level, then genetic testâ€”patients lose motivation between steps)
- Different labs (sometimes AAT level done at Quest, genetic test sent to ARUPâ€”confusing)
- Delayed results (4-6 weeksâ€”patients forget, don't follow up)

**Impact**: 25% of patients with abnormal AAT level never complete genetic test (lost to follow-up)

---

### 4. Awareness Barrier

**Problem**:

- Patients don't know genetic testing needed (doctor says "Your AAT is low, you have AATD"â€”patient thinks they're done)
- Family members don't test (patient diagnosed, but siblings, children not screenedâ€”genetic cascade testing rare)
- Carriers not prioritized (MZ, MS patients dismissedâ€”"You're just a carrier, no big deal"â€”but new research shows health risks)

**Impact**: Only 10% of at-risk family members get tested (should be 100%)

---

## Simplification Strategies

### Strategy 1: Combined AAT + Genetic Testing (Single Sample)

**Concept**: One blood draw â†’ both AAT level AND genetic test (results together)

**How**:

- Lab processes sample for AAT level (nephelometry or immunoassay)
- Same sample used for genetic testing (DNA extraction, sequencing)
- Results reported together (e.g., "AAT level: 45 mg/dL, Genotype: ZZ")

**Benefits**:

- âœ… Patient convenience (one lab visit, not two)
- âœ… Higher completion (no drop-off between tests)
- âœ… Faster results (processed in parallelâ€”2-3 weeks total vs. 4-6 weeks)

**Barriers**:

- Lab workflow (some labs don't offer both testsâ€”need partnership with full-service lab)
- Cost (genetic test still $200-$1,000â€”cost barrier remains)

**Foundation Action**:

- Partner with lab (e.g., Invitae, GeneDxâ€”negotiate bundled pricing, promote to doctors)
- Educate doctors ("Order both tests upfrontâ€”saves time, improves patient compliance")

---

### Strategy 2: At-Home Genetic Testing Kit

**Concept**: Mail-in kit (like 23andMe)â€”patient orders online, spits or pricks finger, mails sample, gets results online

**How**:

- Foundation partners with DTC genetics company (Invitae, Color Genomics, 23andMe)
- Patient orders kit ($100â€”Foundation subsidizes if uninsured)
- Sample collection at home (saliva or finger prickâ€”no clinic visit)
- Ship to lab (pre-paid envelope)
- Results in 2-3 weeks (online portal + genetic counseling included)

**Benefits**:

- âœ… Accessible (no clinic visitâ€”rural, international patients can test)
- âœ… Convenient (do at home, on your schedule)
- âœ… Affordable (partner negotiates pricingâ€”$50-$100 vs. $500+)
- âœ… Genetic counseling included (results explained by counselorâ€”not just raw data)

**Barriers**:

- Sample quality (saliva or finger prick less reliable than venous bloodâ€”but acceptable for genetic testing)
- Doctor acceptance (some doctors don't trust DTC testsâ€”need education)
- State regulations (NY, NJ restrict DTC testingâ€”need workarounds)

**Foundation Action**:

- Launch at-home testing program (Year 2â€”see detailed plan below)

---

### Strategy 3: Free Testing for Uninsured/Low-Income

**Concept**: Foundation pays for genetic testing (for patients who can't afford)

**How**:

- Patient applies (online formâ€”income verification, proof of abnormal AAT level)
- Foundation approves (income <200% FPLâ€”~$60K family of 4)
- Foundation pays lab directly ($200-$400â€”negotiated rate with partner lab)
- Patient gets free testing

**Benefits**:

- âœ… Removes cost barrier (100% coverage for low-income patients)
- âœ… Health equity (ensure all patients diagnosed, regardless of ability to pay)

**Year 1 Budget**: $100K (subsidize 250-500 tests)

**Year 3 Budget**: $500K (subsidize 1,250-2,500 tests)

---

### Strategy 4: Genetic Cascade Testing Program

**Concept**: Once patient diagnosed, test ALL first-degree relatives (siblings, children, parents)

**How**:

- Proband (diagnosed patient) consults genetic counselor (Foundation-funded)
- Counselor creates family tree (identify at-risk relatives)
- Foundation offers free testing (first-degree relativesâ€”50% chance of being carrier or affected)
- Results reported with genetic counseling (explain risk, next steps)

**Benefits**:

- âœ… Early diagnosis (catch AATD before symptomsâ€”start treatment early)
- âœ… Family planning (carriers know risk for future children)
- âœ… Exponential reach (1 diagnosis â†’ 5-10 relatives tested â†’ 2-3 more cases found per family)

**Year 1 Goal**: 100 families (500 relatives tested, 50 new diagnoses expected)

**Year 3 Goal**: 500 families (2,500 relatives tested, 250 new diagnoses)

---

## Consumer Genetics Partnership

### Partnership with 23andMe, AncestryDNA, or Similar

**Opportunity**: 30+ million Americans have taken DTC genetic tests (23andMe, AncestryDNAâ€”data already exists)

**Problem**: Most DTC tests don't report AATD variants (or report incompletelyâ€”miss rare variants)

**Solution**: Partner with DTC company to:

1. **Flag AATD Variants**: Update their database (identify customers with S, Z, rare variants)
2. **Notify Customers**: "Your genetic data suggests AATD riskâ€”get clinical testing" (email, app notification)
3. **Refer to Foundation**: Provide link to Foundation (education, testing assistance, specialist referral)

---

### Partnership Model (Proposed)

**Phase 1: Data Mining (Year 1)**:

- 23andMe/Ancestry agrees to reanalyze existing customer data (30M+ samples)
- Look for SERPINA1 variants (S, Zâ€”common variants included in standard SNP arrays)
- Identify 300K-500K customers with potential AATD (carriers or affected)

**Phase 2: Customer Notification (Year 2)**:

- Email campaign ("Your DNA shows potential Alpha-1 riskâ€”learn more")
- Link to Foundation website (educational resources, testing assistance)
- Offer clinical-grade confirmation (partner labâ€”$100 test, Foundation subsidizes if needed)

**Phase 3: Expanded Testing (Year 3+)**:

- DTC company adds comprehensive AATD panel (test all known variants, not just S and Z)
- Include AATD in standard health reports (currently hidden or not reported)
- Partner with Foundation (every AATD result includes Foundation resources)

---

### Precedent: 23andMe + Other Disease Foundations

**Examples**:

- **BRCA (Breast Cancer)**: 23andMe reports BRCA1/BRCA2 variants (breast/ovarian cancer riskâ€”FDA approved)
- **Parkinson's**: Michael J. Fox Foundation partnered with 23andMe (research studyâ€”recruited 100K+ participants)
- **Alzheimer's**: 23andMe reports APOE variants (Alzheimer's riskâ€”opt-in)

**AATD is Precedented**: Other rare genetic diseases reported by DTC tests (Foundation can negotiate similar partnership)

---

### Expected Impact

**Data Mining**: 300K-500K customers flagged (potential AATD carriers or affected)

**Conversion**: 10% follow through with clinical testing (30K-50K new diagnoses over 5 years)

**Family Cascade**: Each diagnosis â†’ 3-5 relatives tested â†’ 60K-100K additional tests (20K-30K new diagnoses)

**Total**: 50K-80K new diagnoses (vs. current 2K/yearâ€”25-40x increase)

---

## At-Home Testing Program

### Program Design: "AATD Home Test Kit"

**What Patient Receives**:

- Test kit (saliva collection tube OR finger prick lancet + collection card)
- Instructions (easy-to-follow, pictures, QR code to video tutorial)
- Pre-paid return envelope (USPS or FedEx)
- Genetic counseling voucher (30-min telehealth session included)

**Patient Process**:

1. **Order Kit**: Online (Foundation websiteâ€”$100, or free if uninsured)
2. **Collect Sample**: At home (spit in tube or prick finger, 5 min)
3. **Mail Sample**: Drop in mailbox (pre-paid envelope)
4. **Wait 2-3 Weeks**: Lab processes (DNA extraction, SERPINA1 sequencing)
5. **Receive Results**: Online portal (secure, HIPAA-compliantâ€”genetic counselor explains)
6. **Next Steps**: If abnormal â†’ Foundation connects to specialist, resources

---

### Partnership Lab Options

**Option 1: Invitae** (Preferred):

- Specialty genetic testing company (comprehensive SERPINA1 sequencingâ€”all variants)
- DTC-friendly (existing platform for at-home kits)
- Affordable ($100-$250â€”Foundation negotiates bulk pricing)
- Genetic counseling included (part of their service)

**Option 2: Color Genomics**:

- Similar to Invitae (comprehensive testing, counseling included)
- Slightly higher cost ($250-$400â€”but very comprehensive)

**Option 3: 23andMe** (If partnership established):

- Already have at-home kit infrastructure (30M+ customers tested)
- Would need to add comprehensive AATD panel (currently only S and Z)
- Lowest cost potential ($50-$100â€”economies of scale)

**Recommendation**: Partner with Invitae (Year 1-2), explore 23andMe partnership (Year 3+)

---

### Pricing & Subsidy Model

**Retail Price**: $100/kit (covers lab cost, counseling, Foundation overhead)

**Insurance Reimbursement**: Submit to patient's insurance (many plans cover genetic testingâ€”especially if abnormal AAT level)

**Foundation Subsidy** (For Uninsured/Low-Income):

- Income <150% FPL (~$45K family of 4) â†’ 100% subsidy (free test)
- Income 150-250% FPL (~$45K-$75K) â†’ 50% subsidy ($50 test)
- Income >250% FPL â†’ full price ($100)

**Year 1 Budget**: $50K (subsidize 250-500 tests)

---

### Marketing & Promotion

**Target Audiences**:

1. **Abnormal AAT Level**: Patients who had low AAT but never did genetic test (Foundation Navigator reaches out)
2. **Family Members**: Relatives of diagnosed patients (cascade testing)
3. **High-Risk Individuals**: COPD patients, liver disease patients (promote via support groups, clinics)
4. **Direct-to-Consumer**: Online ads (Facebook, Googleâ€”"Do you have AATD? Test at home")

**Promotion Channels**:

- Foundation website (dedicated pageâ€”order kit, learn more)
- Social media (patient testimonialsâ€”"I tested at home, so easy!")
- Email campaigns (monthly newsletterâ€”feature at-home testing)
- Doctor education (promote to pulmonologists, primary careâ€”"Offer at-home testing to patients")

**Year 1 Goal**: 500 kits distributed

**Year 3 Goal**: 2,500 kits/year

---

## Insurance & Reimbursement

### Current Reimbursement Landscape

**AAT Level Testing**:

- CPT Code: 82103, 82104 (well-establishedâ€”most insurance covers)
- Reimbursement: $50-$150 (standard lab test)

**Genetic Testing**:

- CPT Codes: 81332 (targetedâ€”S and Z only), 81479 (full sequencingâ€”rare variants)
- Reimbursement: Variable ($200-$1,000â€”depends on plan, medical necessity documentation)
- Coverage: 70-80% of plans cover (if abnormal AAT levelâ€”medical necessity)

---

### Improving Reimbursement (Foundation Advocacy)

**Strategy 1: Clinical Utility Evidence**:

- Publish studies (genetic testing changes treatment, improves outcomes)
- ATS/ERS guidelines (recommend genetic testing for all abnormal AATâ€”strengthen recommendations)
- Present to payers (show genetic testing is cost-effectiveâ€”early diagnosis prevents expensive ER visits, hospitalizations)

**Strategy 2: Medicare/Medicaid Coverage**:

- Advocate for universal coverage (Medicareâ€”covers 60M+ Americans, Medicaidâ€”80M+)
- If Medicare covers â†’ commercial plans follow (Medicare sets standard)

**Strategy 3: At-Home Test Reimbursement**:

- Obtain CPT code for at-home genetic test (currently ambiguousâ€”lab-based codes don't clearly apply to DTC)
- Demonstrate equivalence (at-home test = same quality as lab test)
- Year 2-3 Goal: At-home test reimbursed by insurance (removes cost barrier)

---

## Technology Innovation

### Next-Generation Sequencing (NGS) for AATD

**Current**: Most labs use PCR-based genotyping (test only S and Zâ€”miss rare variants)

**Future**: NGS panels (sequence entire SERPINA1 geneâ€”identify ALL variants, including novel mutations)

**Benefits**:

- âœ… Comprehensive (catch rare variantsâ€”null alleles, F, I, M variants)
- âœ… Cost-effective (NGS prices droppingâ€”$100-$200/test now, was $1,000+ 5 years ago)
- âœ… Research value (identify new variantsâ€”contribute to scientific knowledge)

**Foundation Action**:

- Partner with NGS labs (Invitae, GeneDxâ€”promote comprehensive testing)
- Educate doctors ("Don't just test S and Zâ€”order full sequencing")

---

### Whole Genome Sequencing (WGS) Integration

**Vision**: As WGS becomes standard of care (predicted in 10-20 yearsâ€”$100 genome), AATD genotype automatically known

**How**:

- Newborns get WGS at birth (entire genome sequencedâ€”stored for life)
- SERPINA1 variants automatically flagged (no separate test needed)
- High-risk individuals monitored proactively (before symptoms)

**Foundation Role**:

- Advocate for WGS in newborn screening (AATD one of many actionable conditions identified)
- Partner with genomics initiatives (All of Us Research Program, UK Biobankâ€”include AATD in research)

---

### CRISPR Gene Therapy (Futureâ€”But Requires Genetic Testing)

**Context**: Gene therapy for AATD in development (clinical trials underwayâ€”edit SERPINA1 gene in liver cells)

**Requirement**: Must know exact genotype (ZZ, SZ, rare nullâ€”therapy tailored to mutation)

**Foundation Action**: Ensure all AATD patients genetically confirmed NOW (so they're ready when gene therapy approvedâ€”predicted 2030-2035)

---

## Implementation Roadmap

### Year 1: Foundation & Partnerships (2026)

**Q1-Q2: Setup**:

- Hire Genetic Testing Coordinator (full-timeâ€”manage partnerships, subsidies, patient support)
- Negotiate lab partnerships (Invitae, GeneDxâ€”bulk pricing, quality agreements)
- Develop subsidy program (application process, income verification, payment to labs)

**Q3-Q4: Pilot Launch**:

- Free testing for 250 uninsured patients (prove model, gather feedback)
- Cascade testing pilot (20 familiesâ€”test relatives, measure uptake)
- Begin 23andMe partnership discussions (explore data mining, DTC integration)

**Year 1 Metrics**:

- 500 genetic tests subsidized (250 uninsured, 250 cascade testing)
- $100K spent (subsidies)
- 90% testing completion rate (vs. 25% baselineâ€”huge improvement)

---

### Year 2: At-Home Testing Launch (2027)

**Q1-Q2: Development**:

- Partner with Invitae (at-home kitâ€”saliva or finger prick)
- Build online ordering system (Foundation websiteâ€”order kit, pay, track status)
- Train genetic counselors (Foundation hires 2 counselorsâ€”explain results to patients)

**Q3-Q4: Public Launch**:

- Market at-home testing (social media, email, patient outreachâ€”"Test at home, $100 or free")
- Distribute 500 kits (Year 2 goal)
- Measure outcomes (completion rate, new diagnoses, patient satisfaction)

**Year 2 Metrics**:

- 1,000 genetic tests total (500 subsidized in-clinic, 500 at-home)
- $150K spent
- At-home kit completion rate: 85%+ (highâ€”because done at home, less friction)

---

### Year 3: Scale & 23andMe Partnership (2028)

**Q1-Q2: Expansion**:

- Scale at-home testing (2,500 kits/year)
- Launch genetic cascade testing (500 familiesâ€”2,500 relatives tested)

**Q3-Q4: 23andMe Partnership** (If Negotiated):

- Data mining (identify 300K-500K customers with potential AATD)
- Customer notification (email campaignâ€”offer clinical confirmation)
- Monitor conversions (track how many get clinical testing)

**Year 3 Metrics**:

- 5,000 genetic tests total (2,500 at-home, 2,500 cascade)
- $500K spent
- 23andMe partnership: 30K-50K customers notified (3K-5K convert to clinical testingâ€”Year 3-5)

---

## Success Metrics

### Testing Volume

**Baseline** (Pre-Foundation): 10,000 genetic tests/year (USâ€”mostly research programs)

**Year 1**: 500 additional tests (Foundation-subsidized)

**Year 3**: 5,000 additional tests

**Year 5**: 20,000 additional tests (2x current testing volume)

**Year 10**: 100,000 additional tests (10x baselineâ€”with 23andMe partnership, at-home testing, cascade testing)

---

### Diagnostic Yield

**New Diagnoses per Test**:

- Targeted testing (abnormal AAT) â†’ 80% positive (ZZ, SZ, rare variants)
- Cascade testing (relatives) â†’ 30% positive (50% carriers, 10% affected)
- 23andMe follow-up â†’ 60% positive (pre-screenedâ€”higher yield)

**Year 1**: 400 new diagnoses (500 tests Ã— 80% yield)

**Year 3**: 3,000 new diagnoses (5,000 tests Ã— 60% average yield)

**Year 5**: 12,000 new diagnoses (20,000 tests Ã— 60%)

**Cumulative (10 Years)**: 150,000 new diagnoses (vs. 20,000 without Foundationâ€”7.5x increase)

---

### Cost Efficiency

**Cost per Diagnosis**:

- Traditional testing: $500-$1,000 (insurance or patient pays)
- Foundation-subsidized: $250 (bulk pricing, efficiency)
- At-home testing: $100 (patient pays) or $50 (Foundation subsidizes)

**Foundation Investment**: $5M over 10 years (testing subsidies)

**New Diagnoses**: 150,000 (over 10 years)

**Cost per Diagnosis**: $33 (incredibly cost-effectiveâ€”early diagnosis saves $100K+ in prevented complications)

---

### Health Equity Impact

**Uninsured/Low-Income Testing**:

- Baseline: <10% of uninsured complete genetic testing
- With Foundation: 90%+ complete testing (free or subsidized)

**Rural Access**:

- Baseline: 50% of rural patients complete testing (travel barrier)
- With At-Home Testing: 90%+ complete (no travel needed)

**Minority Representation**:

- Baseline: 80% of tested patients are white (health disparities)
- Foundation Goal: Match US demographics (60% white, 40% minoritiesâ€”targeted outreach, language access)

---

## Budget (5-Year Projection)

**Year 1**: $150K

- Testing subsidies: $100K (500 tests Ã— $200 average subsidy)
- Genetic Testing Coordinator: $50K (salary)

**Year 2**: $250K

- Testing subsidies: $150K (1,000 tests)
- Genetic counselors: $60K (1 part-time)
- At-home kit development: $40K (setup costs)

**Year 3**: $600K

- Testing subsidies: $500K (5,000 tests)
- Genetic counselors: $120K (2 full-time)

**Year 5**: $2M

- Testing subsidies: $1.6M (20,000 tests)
- Staff: $300K (5 counselors, 2 coordinators)
- 23andMe partnership: $100K (marketing, outreach)

**5-Year Total**: $5M

**ROI**: 150,000 new diagnoses (early treatment saves $100K+ per patientâ€”$15B+ healthcare savings)

---

## Summary

**DNA Testing Simplification = Key to Ending Diagnostic Delay**:

- âœ… **Remove Barriers**: Cost (subsidies), access (at-home testing), complexity (combined AAT+genetic test)
- âœ… **Increase Access**: At-home kits (rural, international), DTC partnerships (23andMeâ€”reach 30M+ customers)
- âœ… **Family Cascade**: Test relatives proactively (exponential reachâ€”1 diagnosis â†’ 10 relatives tested)
- âœ… **Health Equity**: Ensure all patients diagnosed (regardless of income, location, race)

**5-Year Goal: 10x Increase in Genetic Testing â†’ 150,000 New Diagnoses â†’ Transform AATD Landscape**

**"Every diagnosis starts with a test. Let's make testing easy."**

---

**Need Genetic Testing?**

**Mark Egly Foundation Genetic Testing Program**
ðŸ“ž Phone: 1-800-AATD-TEST
ðŸ“§ Email: testing@markeglyfoundation.org
ðŸ  At-Home Testing: MarkEglyFoundation.org/GetTested

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Testing is the first step to treatment. Let's make it easy for everyone."_

**â€” Mark Egly Foundation**
